Algernon Pharmaceuticals Stock Performance
| AGNPF Stock | USD 0.06 0.01 19.05% |
On a scale of 0 to 100, Algernon Pharmaceuticals holds a performance score of 5. The firm shows a Beta (market volatility) of 2.79, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Algernon Pharmaceuticals will likely underperform. Please check Algernon Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Algernon Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Algernon Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Algernon Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.4 M | |
| Total Cashflows From Investing Activities | -144.6 K |
Algernon |
Algernon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5.20 in Algernon Pharmaceuticals on December 9, 2024 and sell it today you would earn a total of 0.80 from holding Algernon Pharmaceuticals or generate 15.38% return on investment over 90 days. Algernon Pharmaceuticals is currently producing 0.5667% returns and takes up 8.2584% volatility of returns over 90 trading days. Put another way, 73% of traded otc stocks are less volatile than Algernon, and 89% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Algernon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Algernon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Algernon Pharmaceuticals, and traders can use it to determine the average amount a Algernon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0686
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AGNPF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.26 actual daily | 73 73% of assets are less volatile |
Expected Return
| 0.57 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Algernon Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Algernon Pharmaceuticals by adding it to a well-diversified portfolio.
Algernon Pharmaceuticals Fundamentals Growth
Algernon OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Algernon Pharmaceuticals, and Algernon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Algernon OTC Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Cash And Equivalents | 872.84 K | |||
| Cash Per Share | 0.44 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (2.91 M) | |||
| Earnings Per Share | (2.28) X | |||
| Total Asset | 8.14 M | |||
About Algernon Pharmaceuticals Performance
By analyzing Algernon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Algernon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Algernon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Algernon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. Algernon Pharmaceuticals is traded on OTC Exchange in the United States.Things to note about Algernon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Algernon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Algernon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Algernon Pharmaceuticals is way too risky over 90 days horizon | |
| Algernon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Algernon Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Algernon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (6.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Algernon Pharmaceuticals has accumulated about 872.84 K in cash with (2.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Algernon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Algernon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Algernon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Algernon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Algernon Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Algernon Pharmaceuticals' otc stock. These opinions can provide insight into Algernon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Algernon OTC Stock analysis
When running Algernon Pharmaceuticals' price analysis, check to measure Algernon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Algernon Pharmaceuticals is operating at the current time. Most of Algernon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Algernon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Algernon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Algernon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |